178 related articles for article (PubMed ID: 38308422)
1. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
[TBL] [Abstract][Full Text] [Related]
5. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
[TBL] [Abstract][Full Text] [Related]
8. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
12. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
[TBL] [Abstract][Full Text] [Related]
13. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
16. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM; Cicek MS; Larson NB; Davila J; Wang C; Larson MC; Song H; Dicks EM; Harrington P; Wick M; Winterhoff BJ; Hamidi H; Konecny GE; Chien J; Bibikova M; Fan JB; Kalli KR; Lindor NM; Fridley BL; Pharoah PP; Goode EL
Sci Rep; 2014 Feb; 4():4026. PubMed ID: 24504028
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
